A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Non-infectious Anterior Uveitis
Interventions
DRUG

NS2

NS2 ophthalmic drops (0.5%)

DRUG

Prednisolone acetate ophthalmic suspension (1%)

Trial Locations (15)

19107

Mid-Atlantic Retina, Philadelphia

23502

Virginia Eye Consultants, Norfolk

33324

Bascom Palmer Eye Institute, Plantation

48009

Oakland Ophthalmic Surgery, Birmingham

63017

Lifelong Vision Foundation, Chesterfield

64111

Tauber Eye Center, Kansas City

68106

UNMC Stanley Truhlsen Eye Institute, Omaha

77025

Houston Eye Associates, Houston

80401

Colorado Retina Associates,PC, Golden

93534

Hull Eye Center, Lancaster

06518-3144

Eye Center of Southern Connecticut, Hamden

01940

Valley Eye Physicians & Surgeons, Ayer

02114

Ophthalmic Consultants of Boston, Boston

02451

Massachusetts Eye Research and Surgery Institution (MERSI), Waltham

07650

Metropolitan Eye Research & Surgery Institute, Palisades Park

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY